GALDERMA
Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap.
The license updates, issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA (QM1114). One of Galderma’s key innovation pipeline assets in Injectable Aesthetics, RelabotulinumtoxinA is a next-generation liquid neuromodulator in Injectable Aesthetics developed using Galderma’s proprietary PEARL™ technology. This technology preserves the molecule’s integrity, resulting in a highly active, complex-free botulinum toxin A.
“Our commitment to leading innovation in dermatology is reflected in our high-performance operations. These new license updates granted by the Swedish authorities reflect Galderma’s skills and the capacities we are building to support our rapid growth trajectory. As we work to extend our category leadership globally, these new capabilities will increase Galderma’s autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”
ADRIAN MURPHY HEAD OF GLOBAL OPERATIONS GALDERMA
|
Galderma’s center of excellence in Uppsala is one of the company’s four state-of-the-art manufacturing and R&D facilities around the world. Galderma is currently expanding this site in response to growing global demand for science-based premium dermatology solutions. The new facility—scheduled for completion by the end of 2025—will be strategically positioned to cater to the higher demand for injectable aesthetics treatments worldwide and the development of upcoming products. With a modular design that allows for seamless further expansion in the future, this forward-looking approach aligns with both Galderma’s growth strategy and its environment, social and governance (ESG) roadmap.
About RelabotulinumtoxinA (QM1114)
Developed by Galderma, RelabotulinumtoxinA is a highly active, innovative, complex-free and ready-to-use liquid botulinum toxin A with a proprietary strain. Manufactured using a unique state-of-the-art process, it is designed as a liquid. This avoids the need to reconstitute from powder and thus eliminates the variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally, with a view to expanding its neuromodulator portfolio – part of the broadest injectable aesthetics portfolio on the market.
About Galderma
Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618347979/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Université Paris-Saclay and Owkin: A Unique Alliance to Propel University Medical Research to the Top of the European Rankings Through AI20.11.2025 15:17:00 CET | Press release
Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free - Owkin’s AI co-pilot for biology - for use by Paris-Saclay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120130113/en/ K Pro Free will now be available to the entire Université Paris-Saclay community, and in particular teachers, researchers and doctoral students working in the biomedical sciences. The partnership includes workshops, training sessions and events designed to promote the discovery and adoption of K Pro Free, as well as the co-organization of communication and dissemination initiatives around the use of AI in health. In this way, the partnership will promote user training, but also enrich and continuously improve the co-pilot's models through feedback and use cases from the l’Université Paris-Saclay community. This partnership is part of Université Paris-Saclay’s strategy to integr
Frasca Advances Flight Training Technology with New Visual System Powered by Unreal Engine20.11.2025 15:05:00 CET | Press release
Frasca International, Inc., a FlightSafety International company and leader in flight simulation, today announced the launch of VITAL FVS 100, the next evolution of its visual system technology. Building on the proven TruVision Global platform, VITAL FVS 100 was developed using Epic Games’ Unreal Engine and delivers unprecedented realism, scalability, and innovation in pilot training. The Unreal-powered VITAL FVS 100 system introduces major advancements in visual fidelity and training realism, further enhancing the capabilities of Frasca, a leading developer of flight simulators and training devices. The new system includes physically based renderings, advanced lighting effects, and a new volumetric cloud model that creates dynamic, weather-rich environments. Terrain imagery now includes one-meter resolution coverage for the contiguous United States and Hawaii, with expanded global datasets covering European buildings and tree covered regions. Additionally, enhanced particle effects re
GigaOm Radar for Vector Databases v3 Positions Vespa.ai as a Leader and Outperformer20.11.2025 15:00:00 CET | Press release
Vespa Recognized for Integrated Ranking, Multimodal Search, and Production-Scale AI Performance Vespa.ai, the creator of the AI Search Platform for building and deploying large-scale, real-time AI applications powered by big data, today announced its recognition as a Leader and Outperformer in the GigaOm Radar for Vector Databases v3, marking the company’s third consecutive year being evaluated in GigaOm’s vector database research. Now in its third edition, the report compares 17 leading open source and commercial solutions using GigaOm’s structured evaluation framework. In addition to core table-stakes capabilities, the Radar reviews each vendor’s key features, emerging strengths, and broader business criteria. The shift from Sonar to Radar reflects the technology’s transition into mainstream adoption. GigaOm names Vespa.ai a leader for its ability to manage complex data, optimize results at scale, and support multimodal AI workloads. The report highlights Vespa’s native tensor suppor
Hitit Empowers Airlines to Optimize Crew Leave Planning with Gurobi20.11.2025 15:00:00 CET | Press release
With Crane Crew, one of the products in Hitit’s Crane Solution Suite, dozens of airlines have reduced their planning periods from weeks to minutes. Gurobi Optimization, LLC, the leader in decision intelligence technology, is proud to be the solver of choice for Hitit, a leading global provider of airline and travel IT solutions. Hitit’s Crane Crew Leave Optimizer—one of the key sub-modules of Hitit’s Crane Crew solution—enables airlines to quickly generate optimal leave schedules for thousands of crew members. Powered by Gurobi’s mathematical optimization solver, the tool significantly reduces planning time while improving both operational efficiency and crew satisfaction. Among the many constraints that airlines must consider are operational requirements, business rules, crew seniority, and personal preferences. As such, manual planning efforts can often lead to inefficiencies, crew dissatisfaction, and compliance risks. After switching to Crane Crew, Hitit’s partner airlines have rep
Myonex Appoints Greg Lavin as Chief Executive Officer20.11.2025 15:00:00 CET | Press release
Greg Lavin takes over the CEO role as James Lovett retires and joins the company’s Board of Directors Myonex®, a leading global integrated clinical trial supply solutions and commercial services company, announced today that Greg Lavin, Chief Financial Officer (CFO), will assume the role of Chief Executive Officer (CEO) effective January 1, 2026. A seasoned executive with experience in the pharmaceutical services industry, including senior roles across clinical research organizations, preclinical and laboratory services, and healthcare data analysis, Lavin succeeds James Lovett, who is retiring and will remain on the company’s board of directors to provide strategic guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120250133/en/ Greg Lavin at Myonex's Headquarters in Horsham, PA During his 6-plus years as CFO of Myonex, Lavin has worked closely with Lovett in driving its transformation from a comparator sourcing su
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom